All three Phase 3 trials of the weekly shot ribupatide have finished enrolling, and the head-to-head against semaglutide is ...
Monte Rosa’s NEK7-targeting drug pulled several heart-risk biomarkers toward healthy levels in 108 people with obesity.
Patent cliffs and falling R&D productivity push the biggest players toward other people's science – our report puts numbers ...
The whole-body scan company is launching a research network with 50+ institutions. Early findings come with some big open ...
The company added hormone therapy to its platform and released IBS results from nearly 16,000 members, with caveats attached.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results